Biomarin Pharmaceutical Inc (BMRN)

Debt-to-capital ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	593,095	1,083,020	1,079,080	1,075,140	486,238
Total stockholders’ equity	US$ in thousands	4,951,550	4,603,160	4,265,670	4,100,930	3,122,380
Debt-to-capital ratio		0.11	0.19	0.20	0.21	0.13

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $593,095K ÷ ($593,095K + $4,951,550K)
= 0.11

The debt-to-capital ratio of Biomarin Pharmaceutical Inc has shown a decreasing trend over the past five years. In 2023, the ratio improved to 0.11, down from 0.19 in 2022, indicating a healthier financial position with a lower proportion of debt relative to the company's total capital. This decrease in the debt-to-capital ratio suggests that Biomarin Pharmaceutical Inc has been able to lower its reliance on debt financing in recent years, which may indicate improved financial stability and reduced financial risk. It is important to monitor this ratio in the future to assess the company's ongoing ability to manage its debt levels effectively.